The orphan drug industry has matured considerably in the past decade. With that, more orphan drugs get approved, while pharma and biotechs get closer to launch new and innovative therapies for rare disease patients. Their focus has shifted from early stage challenges to strategies on commercialization, marketing, pricing and reimbursement.
As these companies move from pre-revenue to commercial and start recouping the investments from years of R&D, more capital starts to flood into promising new biotechs, and consolidation starts to rise. VCs investment in orphan drugs biotechs has grown from $101 million in 2005 to over $346 million in 2014, according to Pitch Book.
From VCs to pharma investors, funding is a much more optimistic reality for orphan drug biotechs. However there are still major challenges and uncertainties in terms of how investors assess these investment opportunities. Evolving regulatory guidelines, increased scrutiny over orphan drugs high price, policies risk, and the common R&D failures, are some of the key areas impacting investment decisions in this market.
The lack of a platform for orphan drug biotechs to meet and present their development programs to investors contributed to the launch of Pitch & Partner at the World Orphan Drug Congress USA. In 2017, not only 20+ biotechs startups will be pitching their companies, but a groups of VCs, a new orphan drug/rare disease investment index and successfully funded biotechs will present at
Pitch & Partner.
Ragnar Klingberg, Chief Executive Officer, EmeraMed
Marc Martinell, Chief Executive Officer, Minoryx Therapeutics
Stephen Markus, Chief Executive Officer, Cantex Pharmaceuticals
Amber Salzman, Chief Executive Officer, Adverum Biotechnologies
Marc Wolff, EVP & Chief Financial Officer, Sancilio Pharmaceuticals
Gary Mathias, Chief Executive Officer, Thetis Pharmaceuticals
S H Lau, Chief Executive Officer, New Biotic LLC
John Maslowski, Chief Executive Officer, Fibrocell